ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

NCI, NHGRI plan $100-million, three-year feasibility test for cancer genome project. NCI to establish biospecimen office.

September 23, 2005

In Brief: Wilson Names Director, MCW cancer Center; UAB Cancer Center Makes Three Appointments

February 9, 1996

NCI Still Trying To Broaden Group B Drug Distribution

May 5, 1978

Signet Cell A Rising Trend In Patients Under Age 40

November 25, 2011

NCI National Lab’s Budget to Grow Over Its $299.2 Million FY2013 Level

February 28, 2014

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

May 4, 2012